id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2011-0007,FDA,FDA-2022-E-2011,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-01-27T05:00:00Z,2025,1,2025-01-27T05:00:00Z,,2025-01-27T16:59:11Z,,0,0,090000648690058b
FDA-2022-E-2011-0006,FDA,FDA-2022-E-2011,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-02-27T05:00:00Z,2024,2,2024-02-27T05:00:00Z,,2024-02-27T15:45:08Z,,0,0,09000064863e558d
FDA-2022-E-2011-0005,FDA,FDA-2022-E-2011,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:12:16Z,,0,0,0900006486365699
FDA-2022-E-2011-0004,FDA,FDA-2022-E-2011,Determination of Regulatory Review Period for Purposes of Patent Extension; LYBALV,Notice,Determinations,2023-12-21T05:00:00Z,2023,12,2023-12-21T05:00:00Z,2024-02-21T04:59:59Z,2023-12-21T15:32:46Z,2023-28094,0,0,090000648634e3d5
FDA-2022-E-2011-0003,FDA,FDA-2022-E-2011,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-09-28T04:00:00Z,2022,9,2022-09-28T04:00:00Z,,2022-09-28T20:28:55Z,,0,0,090000648537ac33
FDA-2022-E-2011-0001,FDA,FDA-2022-E-2011,Letter from U S Patent and Trademark Office,Other,Letter(s),2022-08-25T04:00:00Z,2022,8,2022-08-25T04:00:00Z,,2022-08-25T13:53:24Z,,0,0,09000064852734ff
FDA-2022-E-2011-0002,FDA,FDA-2022-E-2011,"Patent Term Extension Application for LYBALVI® Patent No 9,126,977",Other,Application,2022-08-25T04:00:00Z,2022,8,2022-08-25T04:00:00Z,,2022-08-25T13:54:53Z,,0,0,0900006485273901